|Articles|April 27, 2018

Contagion

  • April 2018
  • Volume 3
  • Issue 2

Arming Health Care Providers Against Growing Antimicrobial Resistance

Antibiotic resistance continues to grow, and it’s plaguing health care providers and patients alike.

Antibiotic resistance continues to grow, and it’s plaguing health care providers and patients alike. Despite initiatives from the US Centers for Disease Control and Prevention’s Antibiotic Resistance Solutions Initiative,1 and the commitment of multiple organizations to the World Health Organization’s Global Antimicrobial Resistance Surveillance System to assemble data on antimicrobial resistance around the world, a startling 2 million individuals become infected with resistant bacteria and 23,000 die from resistant infections each year.1 New antibiotics are continually being developed, but only a handful of those pipeline therapies are reported to be effective against resistant priority pathogens.2 As fast as new antibiotics are being developed, bacteria are evolving even faster, and infections that were once treatable are quickly on their way to becoming incurable.

It should come as no surprise, then, that many of the articles in this issue focus on the problem of antimicrobial resistance. Health care providers are now faced with these once-rare infections every day—they must be equipped with best practices on how to handle them. From “Treatment Options to Address the Threat of Carbapenem-Resistant Enterobacteriaceae” to “Long-Acting Anti-MRSA Agents: One Dose to Cure?”, the expert contributions in this issue provide timely and relevant information to help providers battle these superbugs.

Furthermore, with organizations such as the Center for Disease Dynamics, Economics & Policy in Washington, DC, purporting that by the year 2030, antibiotic consumption will increase by as much as 200% if health care providers keep moving forward with their current prescribing practices,3 we need to ensure that all members of the health care team, such as nurses, are actively involved in stewardship. The war on antimicrobial resistance will not be won alone, but with the commitment of every player in the game, we might just live to fight another day.

I trust you will learn from the expert-contributed reporting, built on smart insights and in-depth stories, in this magazine. I also recommend you visit our website, ContagionLive.com, for real-time updates on the shifts rippling through the world of infectious disease.

Stay informed and thanks for reading.

Mike Hennessy, Sr

Chairman and CEO


Related to this article

New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Treatment of Latent Tuberculosis in a Trice
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.
Drawing Borders Around a Borderless Specialty
Editor in chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the proposed OMB rule restricting federal grants for international research collaboration, and how it threatens infectious disease medicine's inherently borderless surveillance networks, publication access, and knowledge-sharing systems.